StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.99−0.25 (-4.77%)

Close on Nov 17, 2026Market cap $489.46MP/E –Yield –

Earnings

aTYR PHARMA's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$7.43
Latest guidance
Issued
Aug 7, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of aTYR PHARMA's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close––-$7.43Release
Q2 FY2026ended Jun 30, 2026Aug 7, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 11, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026after the close––-$0.14Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close–––Release
Q2 FY2025ended Jun 30, 2025Aug 8, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close––-$0.17Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025after the close––-$0.18Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close––-$0.23Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close––-$0.23Release
Q1 FY2024ended Mar 31, 2024May 2, 2024after the close––-$0.23Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

aTYR PHARMA's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
annualized operating expenses reductionQ4 FY2026$13.00M–NewAug 7, 2026

Guidance history

Every forecast aTYR PHARMA put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 7, 2026annualized operating expenses reductionQ4 FY2026$13.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases aTYR PHARMA filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Results
  7. Results
  8. News
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?